A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Napabucasin (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Cancer
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 22 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 03 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.